Regulatory PathRegulatory requirements compared

Active substances

Amlodipine + Irbesartan

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
APROVASC 150MG/10MG F.C.TABLET150,10 mg,mgTablet · Oral use28 BlisterSAR 95.65NCE · Prescriptionsanofi-aventis de Mexico, S.A. de C.V.Valid
APROVASC 150MG/5MG F.C.TABLET150,5 mg,mgTablet · Oral use28 BlisterSAR 95.65NCE · Prescriptionsanofi-aventis de Mexico, S.A. de C.V.Valid
APROVASC 300MG/10MG F.C.TABLET300,10 mg,mgTablet · Oral use28 BlisterSAR 135.95NCE · Prescriptionsanofi-aventis de Mexico, S.A. de C.V.Valid
APROVASC 300MG/5MG F.C.TABLET300,5 mg,mgTablet · Oral use28 BlisterSAR 135.95NCE · Prescriptionsanofi-aventis de Mexico, S.A. de C.V.Valid
Gizamlo300,10 mg,mgFilm-coated tablet · Oral use30 BlisterSAR 61.10Generic · PrescriptionDAR ALDAWAValid
Gizamlo300,5 mg,mgFilm-coated tablet · Oral use30 BlisterSAR 61.10Generic · PrescriptionDAR ALDAWAValid
Gizamlo150,5 mg,mgFilm-coated tablet · Oral use30 BlisterSAR 61.10Generic · PrescriptionDAR ALDAWAValid
REDUVASC 150MG/10MG F.C.TABLET150,10 mg,mgFilm-coated tablet · Oral use28 BlisterSAR 81.30Generic · PrescriptionTabuk Pharmaceutical Manufacturing CompanyValid
REDUVASC 150MG/5MG F.C.TABLET150,5 mg,mgFilm-coated tablet · Oral use28 BlisterSAR 81.30Generic · PrescriptionTabuk Pharmaceutical Manufacturing CompanyValid
REDUVASC 300MG/10MG F.C.TABLET300,10 mg,mgFilm-coated tablet · Oral use28 BlisterSAR 115.55Generic · PrescriptionTabuk Pharmaceutical Manufacturing CompanyValid
REDUVASC 300MG/5MG F.C.TABLET300,5 mg,mgFilm-coated tablet · Oral use28 BlisterSAR 115.55Generic · PrescriptionTabuk Pharmaceutical Manufacturing CompanyValid
Indications — CHI Daman Drug Formulary

HYPERTENSION

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.